Cancer and Immune Response: Old and New Evidence for Future Challenges
Open Access
- 1 December 2008
- journal article
- review article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 13 (12), 1246-1254
- https://doi.org/10.1634/theoncologist.2008-0166
Abstract
Learning Objectives: After completing this course, the reader should be able to: Discuss the current scientific background of immunotherapy applied to cancer treatment.Suggest lines of future investigation in the immunotherapy field.Explain the rationale for developing and discuss the current status of new immunotherapeutic approaches in solid tumors. CME This article is available for continuing medical education credit at http://CME.TheOncologist.com Cancer may occur as a result of abnormal host immune system tolerance. Recent studies have confirmed the occurrence of spontaneous and induced antitumor immune responses expressed as the presence of tumor-infiltrating T cells in the tumor microenvironment in some cancer models. This finding has been recognized as a good prognostic factor in several types of tumors. Some chemotherapy agents, such as anthracyclines and gemcitabine, are effective boosters of the immune response through tumor-specific antigen overexpression after apoptotic tumor cell destruction. Other strategies, such as GM-CSF or interleukin-2, are pursued to increase immune cell availability in the tumor vicinity, and thus improve both antigen presentation and T-cell activation and proliferation. In addition, cytotoxic T lymphocyte antigen 4–blocking monoclonal antibodies enhance immune activity by prolonging T-cell activation. Strategies to stimulate the dormant immune system against tumors are varied and warrant further investigation of their applications to cancer therapy in the future.Keywords
This publication has 47 references indexed in Scilit:
- Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1New England Journal of Medicine, 2008
- Granulocyte-Macrophage Colony-Stimulating Factor Potentiates Rituximab in Patients With Relapsed Follicular Lymphoma: Results of a Phase II StudyJournal of Clinical Oncology, 2008
- Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast CancerJournal of Clinical Oncology, 2008
- Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanomaProceedings of the National Academy of Sciences, 2007
- Cancer Vaccines: Moving Beyond Current ParadigmsClinical Cancer Research, 2007
- Altered Immunity as a Risk Factor for Non-Hodgkin LymphomaCancer Epidemiology, Biomarkers & Prevention, 2007
- Regulatory T cells, tumour immunity and immunotherapyNature Reviews Immunology, 2006
- Molecular identification of a danger signal that alerts the immune system to dying cellsNature, 2003
- Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741Journal of Clinical Oncology, 2003
- Identification of tumour-associated t-cell epitopes for vaccine developmentNature Reviews Cancer, 2002